SCHEMBL287243

SCHEMBL287243

COC(=O)CC(C)CC(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.40
HSD17B10 Q99714 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
MAPT P10636 2/20 0.34
RAB9A P51151 1/20 0.34
KCNA5 P22460 1/20 0.32
CA12 O43570 2/20 0.32
CA14 Q9ULX7 2/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
TET2 Q6N021 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
RECQL P46063 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18126580 1.00 TSHR (0.40) TSHRHSD17B10MGAMGAASI
SCHEMBL3707278 1.00 TSHR (0.40) TSHRHSD17B10MGAMGAASI
SCHEMBL265822 0.88 TSHR (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL9868411 0.83 ALDH1A1 (0.38) TSHRRAB9AALDH1A1
Alcohol SCHEMBL28286197 0.81 TSHR (0.43) TSHRHSD17B10MGAMGAASI
SCHEMBL20013973 0.81 TSHR (0.41) TSHRHSD17B10MGAMGAASI
SCHEMBL12158758 0.79 MGAM (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL320711 0.79
SCHEMBL14532417 0.79 MGAM (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL148546 0.79 TSHR (0.43) TSHRHSD17B10MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055097-A9 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY INC (US) 2026-02-26 US disclosed
US-20250145611-A1 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY, INC. 2025-05-08 US disclosed
EP-4543439-A2 NRF2 PROTEIN DEGRADERS Ganymede Oncology, Inc. (US) 2025-04-30 EP disclosed
CN-119730847-A NRF2 protein degradation agent 盖尼米德肿瘤学股份有限公司 2025-03-28 CN disclosed
WO-2024006742-A2 NRF2 PROTEIN DEGRADERS DRACEN PHARMACEUTICALS, INC. (US) 2024-01-04 WO disclosed
WO-2024006742-A2 NRF2 PROTEIN DEGRADERS DRACEN PHARMACEUTICALS, INC. (US) 2024-01-04 WO disclosed
WO-2023115203-A1 OXER1 ANTAGONISTS AND USES THEREOF FAIRHAVEN PHARMACEUTICALS INC. (CA) 2023-06-29 WO disclosed
CN-107635961-B Indole analogs as 5-oxo-ETE receptor antagonists and methods of use thereof 皇家学习促进学会/麦吉尔大学 2021-07-20 CN disclosed
EP-3277665-B1 INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) 2020-03-04 EP disclosed
EP-3277665-B1 INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) 2020-03-04 EP disclosed
EP-3277665-A1 INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF The Royal Institution for the Advancement of Learning / McGill University (CA) 2018-02-07 EP disclosed
US-9464048-B2 5-oxo-ETE receptor antagonist compounds FLORIDA INSTITUTE OF TECHNOLOGY (US) 2016-10-11 US disclosed
WO-2016154749-A1 INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2016-10-06 WO disclosed
WO-2016154749-A1 INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2016-10-06 WO disclosed
US-20140323535-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2014-10-30 US disclosed
EP-2427430-B1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS UNIV MCGILL (CA) 2014-09-10 EP disclosed
US-8809382-B2 5-oxo-ETE receptor antagonist compounds THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2014-08-19 US disclosed
US-20120122942-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS FLORIDA INSTITUTE OF TECHNOLOGY 2012-05-17 US disclosed
EP-2427430-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS The Royal Institution for the Advancement of Learning / McGill University (CA) 2012-03-14 EP disclosed
WO-2010127452-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122942-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS OXER1, PTGIR, EDNRA TSHR 739/4885HSD17B10 2347/4885MGAM 3695/4885
US-20140323535-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS OXER1, PTGIR, EDNRA TSHR 739/4885HSD17B10 2347/4885MGAM 3695/4885
US-20260055097-A9 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 TSHR 2615/4885HSD17B10 346/4885MGAM 3637/4885
US-20250145611-A1 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 TSHR 2255/4885HSD17B10 2063/4885MGAM 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.